Contents
On this page
- Purpose and deliberate limits of CONSORT
- The structure of the 25-item checklist
- Association between specific reporting gaps and exaggerated effects
- The CONSORT flow diagram as a required element
- CONSORT extensions for designs beyond the standard parallel trial
- Adoption of CONSORT and its measured effect on reporting quality
- The CONSORT extension for trial abstracts
Academy · Research Data, Analytics & AI · CONSORT Checklist
The CONSORT Checklist for Reporting Randomized Trials: Structure, Evidence Base and Flow Diagram
The 30-item CONSORT 2025 checklist and its required flow diagram exist because incomplete trial reporting can conceal bias, not merely affect style. For example, failure to report the method of allocation concealment is associated with exaggerated treatment effects in methodological research cited directly by the CONSORT Group.
CONSORT, the Consolidated Standards of Reporting Trials, is a reporting guideline built around a checklist and a required participant flow diagram, developed to ensure that reports of randomized controlled trials contain the specific information a reader needs to judge a trial’s internal validity and interpret its results correctly. It is not a guideline for designing or conducting a trial; it specifies what a published report of a completed trial must state, so that two readers of the same completed study would extract the same facts about its methods, conduct and results rather than relying on inference or on the authors’ own account of what was important. CONSORT 2025 provides a 30-item checklist and participant flow diagram for reporting randomised trials. It updates CONSORT 2010, which itself updated the original 1996 statement and its 2001 revision, and CONSORT remains the dominant reporting standard adopted, in whole or with extensions, by the large majority of major biomedical journals publishing randomized trials.
Learning objectives
- Why CONSORT exists as a reporting standard rather than a trial-design or trial-conduct standard
- The documented link between specific missing reporting items and exaggerated treatment effect estimates
- What the CONSORT flow diagram is required to show, and why it matters beyond the checklist's text items
Common misconceptions
- “CONSORT compliance is mainly about formatting a paper the way a journal expects, not about the trial's actual evidence quality.” The CONSORT Group’s explanation and elaboration document cites methodological research finding that trials that fail to report adequate allocation concealment and blinding status are associated with exaggerated estimates of treatment effect compared with trials that report these items clearly; specific CONSORT items therefore reflect real risk of bias in a trial’s results, not merely a reporting convention.
Purpose and deliberate limits of CONSORT
CONSORT addresses the reporting of a randomized trial after it has been conducted, not the design or conduct of the trial itself; a well-designed trial can still be reported incompletely, and a CONSORT-compliant report cannot retrospectively correct flaws in a trial’s design or conduct. The CONSORT 2010 statement, published by Schulz, Altman and Moher on behalf of the CONSORT Group, states this distinction explicitly and presents the checklist as a tool for ensuring transparent, complete reporting of what was done and found, so that readers, including peer reviewers, can assess the methodological quality of the trial independently rather than relying on the authors’ own characterization of their work1. The core version of the guideline applies to the most common design, the two-group parallel trial, with separate official extensions covering other designs, including cluster randomized trials, non-inferiority and equivalence trials, and pragmatic trials, each adapting the core checklist items to the specific reporting requirements of that design.
The structure of the 25-item checklist
In CONSORT 2010, the 25 items were organized under six headings following the conventional structure of a trial report: title and abstract (item 1, which requires identification as a randomized trial in the title), introduction (background and objectives), methods (covering trial design, participants, interventions, outcomes, sample size, randomization including the specific method of sequence generation and allocation concealment, blinding, and statistical methods), results (participant flow, recruitment and follow-up dates, baseline data, numbers analyzed, outcomes and estimation, ancillary analyses, and harms), discussion (limitations, generalizability, and interpretation), and other information (registration, protocol access, and funding)1. Several of these items, particularly the randomization-related items in the methods section, were deliberately specified in this detail because methodological research had already identified them as the points at which incomplete reporting is associated with differences in the trustworthiness of a trial’s results.
Association between specific reporting gaps and exaggerated effects
The CONSORT Explanation and Elaboration document, published alongside the main statement, cites methodological research specifically linking inadequate reporting of allocation concealment and blinding to larger, probably exaggerated, estimates of treatment effect when compared with trials reporting these items adequately2. This is the empirical basis for treating allocation concealment and blinding as checklist items with real evidentiary weight rather than as procedural formalities: a trial that does not report how its allocation sequence was concealed from those enrolling participants cannot be distinguished, from the report alone, from a trial in which concealment failed and selection bias was introduced, and the research cited by the CONSORT Group found that trials in the first category report, on average, different (typically larger) effect sizes than trials that clearly document adequate concealment2. This is why CONSORT's methods-section items ask specifically for the mechanism of concealment, not merely a statement that the trial was "randomized" or "blinded."
The CONSORT flow diagram as a required element
Alongside the 30-item text checklist of CONSORT 2025, CONSORT requires a flow diagram tracking participants through four stages: enrollment, allocation to study groups, follow-up, and final analysis, including the number of participants at each stage and the specific reasons for any exclusions or losses. The diagram is required because a trial’s reported effect estimate can be systematically distorted by differential dropout between arms, that is, participants in one group leaving the study at a different rate or for different reasons from those in the other, which a prose summary in the results section may leave implicit or omit entirely. Presenting the numbers at each stage, and the stated reasons for loss, in a single standardized diagram enables readers to check directly for this pattern without reconstructing it from figures dispersed across the results section, which is why CONSORT treats the flow diagram as a required element of a compliant trial report rather than an optional illustrative figure.
CONSORT extensions for designs beyond the standard parallel trial
Because the core CONSORT checklist is built around the two-group parallel design, the CONSORT Group has published official extensions adapting it to other trial designs and reporting needs as these have become common in practice. These include extensions for cluster randomized trials, in which randomization occurs at the level of a group (such as a clinic or school) rather than an individual participant; for non-inferiority and equivalence trials, in which the analytic aim is to demonstrate that a new treatment is not meaningfully worse than an existing one rather than to demonstrate superiority; for pragmatic trials designed to reflect routine clinical practice; and for trials of non-pharmacologic treatments such as surgical or psychotherapeutic interventions, in which blinding and standardization raise different issues from those in a typical drug trial5. Authors reporting a trial in one of these categories are expected to apply the modified items of the relevant extension alongside, or in some cases in place of, the corresponding core items, rather than relying on the core checklist alone and assuming that it adequately covers the reporting requirements of their design.
Adoption of CONSORT and its measured effect on reporting quality
CONSORT has been endorsed by a large number of biomedical journals and major editorial organizations, including the International Committee of Medical Journal Editors, which recommends it among the reporting guidelines authors should follow for the relevant study type6. Methodological research evaluating the effect of journal endorsement has found that trial reports published in journals that formally require CONSORT compliance tend to report key methodological items, including random sequence generation and allocation concealment, more completely than reports in journals without that requirement, which indicates that the adoption of the guideline, not merely its publication, is associated with improved reporting in practice7. For this reason, submitting to a CONSORT-endorsing journal, and using its checklist as a drafting tool from the beginning of manuscript preparation rather than as a final compliance exercise, increases the likelihood that the methodological strengths of the underlying trial are clearly visible in the published report.
The CONSORT extension for trial abstracts
Because a trial’s abstract is read far more widely than its full text, the CONSORT Group published a dedicated extension for reporting randomized trials in journal and conference abstracts, developed by Hopewell and colleagues and explained in detail in a 2008 PLoS Medicine paper10. This extension asks authors to state, within the strict word limits typical of an abstract, the trial design, participant eligibility criteria, the interventions compared, the primary outcome, the method of randomization, whether blinding was used, the number of participants randomized and analyzed in each arm, the main results for the primary outcome with a measure of precision, and any important harms or unintended effects, thereby condensing the methodological detail of the full checklist into the limited number of items that an abstract can accommodate10. As with the corresponding PRISMA abstract checklist for systematic reviews, the rationale is that a trial’s abstract is frequently the only part of the report that a clinician making a point-of-care decision will read closely, so its reporting completeness warrants a dedicated, verifiable standard rather than being left to each author’s judgment about what an abstract should include. Authors preparing a trial report for a journal or conference should treat this abstract extension as a companion to the full 30-item CONSORT 2025 checklist, completing both before submission rather than drafting the abstract only once the full manuscript is finished.
Key points
Key points
The CONSORT checklist (30 items in CONSORT 2025) and required flow diagram exist because specific reporting gaps, particularly concerning allocation concealment and blinding, are empirically linked to exaggerated treatment effect estimates, not because of a general preference for thorough reporting; complete, specific reporting of these items enables readers to assess a trial’s risk of bias rather than accepting its conclusions without scrutiny.
Practical application
Practical application
- The specific mechanism of allocation concealment should be reported, not merely the fact that randomization occurred. The method by which the allocation sequence was concealed from those enrolling participants should be stated exactly (for example, a concealed, numbered container system or a centralized randomization service), since this item is linked to distortion of effect size when reported vaguely or omitted.
- The flow diagram should be constructed with exact numbers and reasons at every stage. The number of participants enrolled, allocated, followed up and analyzed in each arm should be reported, with specific reasons for every exclusion or loss, rather than a diagram showing only overall totals.
- The draft should be checked against the full 30-item CONSORT 2025 checklist before submission, not only against the items recalled from memory. The official CONSORT checklist document should be used directly, since several items, including statistical methods and ancillary analyses, are easily reported incompletely without a structured check.
Frequently asked questions
The core CONSORT checklist is built around the standard two-group parallel trial; the CONSORT Group publishes separate official extensions adapting the core items for other designs, including cluster randomized trials, non-inferiority and equivalence trials, and pragmatic trials, and the appropriate extension should be used alongside or instead of the core checklist for those designs.
Many major biomedical and health-science journals require CONSORT-compliant reporting, including submission of a completed checklist and flow diagram, as a condition of considering a randomized trial manuscript for publication, though exact requirements vary by journal and should be checked directly.
Methodological research cited directly in the CONSORT Explanation and Elaboration document found that trials that fail to report adequate allocation concealment are associated with exaggerated treatment effect estimates compared with trials that report it clearly; the specific mechanism, not merely the fact of randomization, therefore carries real evidentiary weight regarding the trial’s risk of bias.
Yes. CONSORT governs reporting completeness, not the quality of trial design or conduct; a trial can report every required item completely and transparently while still having, for example, an underpowered sample or a flawed outcome measure, which is why CONSORT compliance is a necessary but not sufficient condition for trusting a trial’s conclusions.
References
- Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332. read 10 October 2026. View on BMJ
- Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c869. read 10 October 2026. View on BMJ
- Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273(5):408-412. read 10 October 2026. View on JAMA
- CONSORT Group. The CONSORT Flow Diagram. read 10 October 2026. View CONSORT flow diagram resources
- CONSORT Group. CONSORT Extensions. read 10 October 2026. View CONSORT extensions listing
- International Committee of Medical Journal Editors. Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. read 10 October 2026. View ICMJE Recommendations
- Turner L, Shamseer L, Altman DG, Schulz KF, Moher D. Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane review. Syst Rev. 2012;1:60. read 10 October 2026. View on Systematic Reviews
- Campbell MK, Piaggio G, Elbourne DR, Altman DG; CONSORT Group. CONSORT 2010 statement: extension to cluster randomised trials. BMJ. 2012;345:e5661. read 10 October 2026. View on BMJ
- Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-47. read 10 October 2026. View on Annals of Internal Medicine
- Hopewell S, Clarke M, Moher D, et al; CONSORT Group. CONSORT for Reporting Randomized Controlled Trials in Journal and Conference Abstracts: Explanation and Elaboration. PLoS Med. 2008;5(1):e20. read 10 October 2026. View on PLOS Medicine
Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.
How to cite this article
Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.
Pubrica Academy. (2026, October 10). The CONSORT Checklist for Reporting Randomized Trials: Structure, Evidence Base and Flow Diagram. Pubrica. https://pubrica.com/academy/concepts-definitions/consort-checklists/
Pubrica Academy. “The CONSORT Checklist for Reporting Randomized Trials: Structure, Evidence Base and Flow Diagram.” Pubrica, 10 Oct. 2026, pubrica.com/academy/concepts-definitions/consort-checklists/.
Pubrica Academy (2026) The CONSORT Checklist for Reporting Randomized Trials: Structure, Evidence Base and Flow Diagram. Pubrica. Available at: https://pubrica.com/academy/concepts-definitions/consort-checklists/ (Accessed: 15 October 2026).
Pubrica Academy. “The CONSORT Checklist for Reporting Randomized Trials: Structure, Evidence Base and Flow Diagram.” Pubrica. October 10, 2026. https://pubrica.com/academy/concepts-definitions/consort-checklists/
Pubrica Academy, ‘The CONSORT Checklist for Reporting Randomized Trials: Structure, Evidence Base and Flow Diagram’ (Pubrica, 10 October 2026) <https://pubrica.com/academy/concepts-definitions/consort-checklists/> accessed 15 October 2026.
Pubrica Academy. The CONSORT Checklist for Reporting Randomized Trials: Structure, Evidence Base and Flow Diagram. [Internet]. Pubrica; 2026 Oct 10 [cited 2026 Oct 15]. Available from: https://pubrica.com/academy/concepts-definitions/consort-checklists/
Pubrica Academy, “The CONSORT Checklist for Reporting Randomized Trials: Structure, Evidence Base and Flow Diagram,” Pubrica, Oct. 10, 2026. [Online]. Available: https://pubrica.com/academy/concepts-definitions/consort-checklists/
@misc{/la_consort_checklist_reporting_trials_2026,
author = {{Pubrica Academy}},
title = {The CONSORT Checklist for Reporting Randomized Trials: Structure, Evidence Base and Flow Diagram},
howpublished = {Pubrica},
year = {2026},
month = {oct},
url = {https://pubrica.com/academy/concepts-definitions/consort-checklists/},
note = {Accessed: <span data-cite-acc="iso">2026-10-15</span>}
}This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.
CONSORT Pre-Submission Checklist
These high-impact items should be verified before a randomized trial manuscript is submitted.
[ ] Title identifies the study as a randomized trial [ ] Trial design (parallel, cluster, non-inferiority, etc.) stated and matched to the correct CONSORT extension if applicable [ ] Method of random sequence generation stated specifically [ ] Method of allocation concealment stated specifically, not just that randomization occurred [ ] Blinding status stated for participants, care providers, and outcome assessors, with method if blinded [ ] Flow diagram included with exact numbers and stated reasons at enrollment, allocation, follow-up, and analysis stages [ ] Registration number/registry, protocol access, and funding sources stated
Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.
How Pubrica can help
The Pubrica clinical trial reporting team checks manuscripts against the full 30-item CONSORT 2025 checklist and flow-diagram requirements, with particular attention to the randomization-related items that methodological research has linked to bias.